This article presents the position of the Society of Metabolic Health Practitioners (SMHP) regarding therapeutic carbohydrate reduction (TCR) nutrition interventions for type 1 diabetes mellitus (T1DM). A modified Delphi methodology was used to arrive at a consensus consisting of several focus groups, multiple rounds, and an anonymous survey. The field of endocrinology has seen many new advances for the treatment of T1DM including hybrid closed-loop insulin delivery systems and continuous glucose monitors for better glycaemic control, monoclonal antibodies to delay the onset of disease and increased access to paediatric endocrinologists, among many other noteworthy achievements. Despite these advancements, standard of care approaches to T1DM result in higher than acceptable morbidity and mortality, with a high prevalence of microvascular and macrovascular complications. Insulin resistance in type 1 diabetes is an independent risk factor for adverse outcomes even in well controlled type 1 diabetes. In 2021, only 21% of adults with T1DM in the United States achieved the American Diabetes Association’s (ADA’s) target haemoglobin A1C goal of < 7.0%, while data in the paediatric and adolescent population have demonstrated worse glycaemic control. Supported by observational and interventional evidence, the SMHP advocates for the reevaluation of the prevailing nutritional therapy for T1DM with more broad consideration for TCR. The SMHP recommends open access and clinical support for TCR nutrition interventions for individuals with T1DM of all ages and calls upon the medical community to help foster more attention and research on TCR for T1DM.
In conclusion, this consensus statement conducted by the SMHP advocates for open access and clinical support for TCR nutrition interventions for individuals with T1DM across all age groups. As a component of diabetes-focused MNT, TCR nutrition therapy exhibits promising results supported by emerging evidence. It is imperative that individuals diagnosed with T1DM, along with their families, receive comprehensive information, education, and support from their entire healthcare team regarding the option of TCR nutrition interventions. This proactive approach ensures that every patient can make well- informed decisions about the nutrition component of their treatment plan, with TCR being presented as a viable therapeutic option from the outset of diagnosis
Position statements from medical organizations are a good view of changing zeitgeists, and are good references for those in practice. The fact that Total Carbohydrate restriction is a useful option for those treating T1D is documented here.
This makes intuitive sense, as those with T1D are not producing insulin internally, and must dose insulin externally based on what they are eating and glycemic load (exercise, stress, etc). Reducing a glycemic variable appears to make treatment more effective in the above statement.